Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma

References

• SiegelRL, MillerKD, FuchsHE, JemalA. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.2165433433946
   PubMed Web of Science ®Google Scholar
• ColomboN, CreutzbergC, AmantF, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016;27(1):16–41.26634381
   PubMed Web of Science ®Google Scholar
• AmantF, MirzaMR, KoskasM, CreutzbergCL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):37–50. doi:10.1002/ijgo.12612
   PubMed Web of Science ®Google Scholar
• CarlsonMJ, ThielKW, LeslieKK. Past, present, and future of hormonal therapy in recurrent endometrial cancer. Int J Womens Health. 2014;6:429–435.24833920
   PubMedGoogle Scholar
• YenTT, WangTL, FaderAN, ShihIM, GaillardS. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26–35. doi:10.1097/PGP.000000000000058530741844
   PubMed Web of Science ®Google Scholar
• Di TucciC, CaponeC, GalatiG, et al. Immunotherapy in endometrial cancer: new scenarios on the horizon. J Gynecol Oncol. 2019;30(3):e46. doi:10.3802/jgo.2019.30.e4630887763
   PubMed Web of Science ®Google Scholar
• OzaAM, ElitL, BiagiJ, et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160. J Clin Oncol. 2006;24(18_suppl):3003.
   Web of Science ®Google Scholar
• AlonsonMA, WeissmanSM. cDNA cloning and sequence of MAL, a hydrophobic protein associated with human T-cell differentiation. Proc Natl Acad Sci U S A. 1987;84(7):1997–2001. doi:10.1073/pnas.84.7.19973494249
   PubMed Web of Science ®Google Scholar
• PérezP, PuertollanoR, AlonsoMA. Structural and biochemical similarities reveal a family of proteins related to the MAL proteolipid, a component of detergent-insoluble membrane microdomains. Biochem Biophys Res Commun. 1997;232(3):618–621. doi:10.1006/bbrc.1997.63389126323
   PubMed Web of Science ®Google Scholar
• WilsonSH, BaileyAM, NourseCR, MatteiMG, ByrneJA. Identification of MAL2, a novel member of the mal proteolipid family, though interactions with TPD52-like proteins in the yeast two-hybrid system. Genomics. 2001;76(1–3):81–88. doi:10.1006/geno.2001.661011549320
   PubMed Web of Science ®Google Scholar
• de MarcoMC, Martín-BelmonteF, KremerL, et al. MAL2, a novel raft protein of the MAL family, is an essential component of the machinery for transcytosis in hepatoma HepG2 cells. J Cell Biol. 2002;159(1):37–44. doi:10.1083/jcb.20020603312370246
   PubMed Web of Science ®Google Scholar
• PuertollanoR, AlonsoMA. MAL, an integral element of the apical sorting machinery, is an itinerant protein that cycles between the trans-Golgi network and the plasma membrane. Mol Biol Cell. 1999;10(10):3435–3447. doi:10.1091/mbc.10.10.343510512878
   PubMed Web of Science ®Google Scholar
• RumahKR, MaY, LindenJR, et al. The myelin and lymphocyte protein mal is required for binding and activity of clostridium perfringens ε-toxin. PLoS Pathog. 2015;11(5):e1004896. doi:10.1371/journal.ppat.100489625993478
   PubMed Web of Science ®Google Scholar
• LindenJR, MaY, ZhaoB, et al. Clostridium perfringens epsilon toxin causes selective death of mature oligodendrocytes and central nervous system demyelination. mBio. 2015;6(3):e02513. doi:10.1128/mBio.02513-1426081637
   PubMed Web of Science ®Google Scholar
• KhaliliS, JahangiriA, HashemiZS, KhalesiB, Mard-SoltaniM, AmaniJ. Structural pierce into molecular mechanism underlying clostridium perfringens epsilon toxin function. Toxicon. 2017;127:90–99. doi:10.1016/j.toxicon.2017.01.01028089770
   PubMed Web of Science ®Google Scholar
• MeckesDG, MenakerNF, Raab-TraubN. Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation. J Virol. 2013;87(3):1301–1311. doi:10.1128/JVI.02519-1223152522
   PubMed Web of Science ®Google Scholar
• FrankM, van der HaarME, Schaeren-WiemersN, SchwabME. rMAL is a glycosphingolipid-associated protein of myelin and apical membranes of epithelial cells in kidney and stomach. J Neurosci. 1998;18(13):4901–4913. doi:10.1523/JNEUROSCI.18-13-04901.19989634556
   PubMed Web of Science ®Google Scholar
• BergmanY, CedarH. DNA methylation dynamics in health and disease. Nat Struct Mol Biol. 2013;20(3):274–281. doi:10.1038/nsmb.251823463312
   PubMed Web of Science ®Google Scholar
• FrankM, Schaeren-WiemersN, SchneiderR, SchwabME. Developmental expression pattern of the myelin proteolipid MAL indicates different functions of MAL for immature Schwann cells and in a late step of CNS myelinogenesis. J Neurochem. 1999;73(2):587–597. doi:10.1046/j.1471-4159.1999.0730587.x10428054
   PubMed Web of Science ®Google Scholar
• KimT, FiedlerK, MadisonDL, KruegerWH, PfeifferSE. Cloning and characterization of MVP17: a developmentally regulated myelin protein in oligodendrocytes. J Neurosci Res. 1995;42(3):413–422. doi:10.1002/jnr.4904203168583510
   PubMed Web of Science ®Google Scholar
• Schaeren-WiemersN, ValenzuelaDM, FrankM, SchwabME. Characterization of a rat gene, rMAL, encoding a protein with four hydrophobic domains in central and peripheral myelin. J Neurosci. 1995;15(8):5753–5764. doi:10.1523/JNEUROSCI.15-08-05753.19957643216
   PubMed Web of Science ®Google Scholar
• WangZ, WangM, XuX, et al. Studies of MAL gene in human esophageal cancer by RNA in situ hybridization. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2000;17(5):329–331.11024212
   PubMedGoogle Scholar
• XuZ, WangM, CaiY. [MAL gene is down-regulated substantially in human esophageal cancer]. Zhonghua Zhong Liu Za Zhi. 1999;21(4):250–252. Chinese.11776806
   PubMedGoogle Scholar
• MimoriK, ShiraishiT, MashinoK, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene. 2003;22(22):3463–3471. doi:10.1038/sj.onc.120637812776198
   PubMed Web of Science ®Google Scholar
• LindGE, AhlquistT, KolbergM, et al. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med. 2008;6(1):13. doi:10.1186/1479-5876-6-1318346269
   PubMed Web of Science ®Google Scholar
• KalmárA, PéterfiaB, HollósiP, et al. DNA hypermethylation and decreased mRNA expression of MAL, PRIMA1, PTGDR and SFRP1 in colorectal adenoma and cancer. BMC Cancer. 2015;15(1):736. doi:10.1186/s12885-015-1687-x26482433
   PubMed Web of Science ®Google Scholar
• HorneHN, LeePS, MurphySK, AlonsoMA, OlsonJA, MarksJR. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res. 2009;7(2):199–209. doi:10.1158/1541-7786.MCR-08-031419208741
   PubMed Web of Science ®Google Scholar
• Guerrero-PrestonR, HadarT, OstrowKL, et al. Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncol Rep. 2014;32(2):505–512. doi:10.3892/or.2014.326224927296
   PubMed Web of Science ®Google Scholar
• BuffartTE, OvermeerRM, SteenbergenRDM, et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer. 2008;99(11):1802–1807. doi:10.1038/sj.bjc.660477719002170
   PubMed Web of Science ®Google Scholar
• ChoiB, HanT-S, MinJ, et al. MAL and TMEM220 are novel DNA methylation markers in human gastric cancer. Biomarkers. 2017;22(1):35–44. doi:10.1080/1354750X.2016.120154227329150
   PubMed Web of Science ®Google Scholar
• MaruyaS-I, KimH-W, WeberRS, et al. Gene expression screening of salivary gland neoplasms: molecular markers of potential histogenetic and clinical significance. J Mol Diagn. 2004;6(3):180–190. doi:10.1016/S1525-1578(10)60508-915269293
   PubMed Web of Science ®Google Scholar
• BederLB, GunduzM, HotomiM, et al. T-lymphocyte maturation-associated protein gene as a candidate metastasis suppressor for head and neck squamous cell carcinomas. Cancer Sci. 2009;100(5):873–880. doi:10.1111/j.1349-7006.2009.01132.x19445022
   PubMed Web of Science ®Google Scholar
• HutajuluSH, IndrasariSR, IndrawatiLPL, et al. Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. Mol Cancer. 2011;10(1):48. doi:10.1186/1476-4598-10-4821535891
   PubMed Web of Science ®Google Scholar
• SuzukiM, ShiraishiK, EguchiA, et al. Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer. Oncol Rep. 2013;29(4):1308–1314. doi:10.3892/or.2013.226623381221
   PubMed Web of Science ®Google Scholar
• BlaveriE, SimkoJP, KorkolaJE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11(11):4044–4055. doi:10.1158/1078-0432.CCR-04-240915930339
   PubMed Web of Science ®Google Scholar
• SchwartzDR, KardiaSLR, SheddenKA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722–4729.12183431
   PubMed Web of Science ®Google Scholar
• BerchuckA, IversenES, LancasterJM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686–3696. doi:10.1158/1078-0432.CCR-04-239815897565
   PubMed Web of Science ®Google Scholar
• Copie-BergmanC, GaulardP, Maouche-ChrétienL, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94(10):3567–3575. doi:10.1182/blood.V94.10.3567.422k06_3567_357510552968
   PubMed Web of Science ®Google Scholar
• Copie-BergmanC, PlonquetA, AlonsoMA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15(11):1172–1180. doi:10.1097/01.MP.0000032534.81894.B312429796
   PubMed Web of Science ®Google Scholar
• KohnoT, MoriuchiR, KatamineS, YamadaY, TomonagaM, MatsuyamaT. Identification of genes associated with the progression of adult T cell leukemia (ATL). Jpn J Cancer Res. 2000;91(11):1103–1110. doi:10.1111/j.1349-7006.2000.tb00892.x11092974
   PubMedGoogle Scholar
• HsiED, SupSJ, AlemanyC, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol. 2006;125(5):776–782. doi:10.1309/98KLHRDAM5CMDHE216707382
   PubMed Web of Science ®Google Scholar
• MillánJ, PuertollanoR, FanL, RancañoC, AlonsoMA. The MAL proteolipid is a component of the detergent-insoluble membrane subdomains of human T-lymphocytes. Biochem J. 1997;321(Pt 1):247–252. doi:10.1042/bj32102479003426
   PubMed Web of Science ®Google Scholar
• MarazuelaM, AlonsoMA. Expression of MAL and MAL2, two elements of the protein machinery for raft-mediated transport, in normal and neoplastic human tissue. Histol Histopathol. 2004;19(3):925–933.15168355
   PubMed Web of Science ®Google Scholar
• FangY, WangL, WanC, et al. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation. J Clin Invest. 2021;131(1). doi:10.1172/JCI140837
   Web of Science ®Google Scholar
• AntónOM, Andrés-DelgadoL, Reglero-RealN, BatistaA, AlonsoMA. MAL protein controls protein sorting at the supramolecular activation cluster of human T lymphocytes. J Immunol. 2011;186(11):6345–6356. doi:10.4049/jimmunol.100377121508261
   PubMed Web of Science ®Google Scholar
• AmantF, MoermanP, NevenP, TimmermanD, Van LimbergenE, VergoteI. Endometrial cancer. Lancet. 2005;366(9484):491–505. doi:10.1016/S0140-6736(05)67063-816084259
   PubMed Web of Science ®Google Scholar